

All Fields

Medicine · Published 2019 · DOI: 10.5958/0976-5506.2019.02206.x

Share This Paper    

# Association of Human Leukocyte Antigen-(HLA-B 27) Gene Polymorphism with Vitiligo Disease

[Mona N. Al-Terehi](#), [Zainab Abbas Al-Talebi](#), +2 authors [Fathia ATeeq Rajab](#)

Vitiligo have been recorded in different ages in population it is appeared by interaction between different factors causes de-pigmentation in skin, the present study conducted to estimate HLA 27 gene polymorphism in vitiligo patients using single specific primer-polymerase chain reaction (PCR-SSP), DNA was extracted from whole blood for patients and control, then amplification was implemented, the results of demographic show that the means of age were 33.093 and 32.809 for patients and control... [CONTINUE READING](#)

- [View PDF](#) [Save To Library](#) [Create Alert](#) [Cite](#)

[ABSTRACT](#)

[FIGURES, TABLES, AND TOPICS](#)

[25 REFERENCES](#)

[RELATED PAPERS](#)

By clicking accept or continuing to use the site, you agree to the terms outlined in our [Privacy Policy](#), [Terms of Service](#), and [Dataset License](#) [ACCEPT & CONTINUE](#)

All Fields

FAQ Contact Us Sign

Figures and Tables

Categories	Patients	Control	Statistics
Age	35.089 ± 15.05	32.809 ± 15.056	t = 0.0864 p = 0.9280
Sex			
Male	79.54%	80.55%	Chi-square 0.006, P = 0.938
Female	18.18%	19.04%	

Table 1




Figure 1

Categories	Percentages %
Family history	
Yes	36.36
No	63.63

Table 2

Table 3. Genotype frequency in patients and control

Genotype	Patient	Control	Odd ratio
HLA+	4.166%	14.28%	0.2609 CI% 0.0214 to 3.1778
HLA -	95.83%	85.71%	P = 0.2921

Table 3

Topics Discussed in This Paper

- Paget's Disease, Mammary
- Polymerase Chain Reaction
- Pigmentation
- Parkinson Disease

References

Publications referenced by this paper.

SHOWING 1-10 OF 25 REFERENCES

SORT BY Influence ▾

Application of PCR-SSP method for HLA-B\*27 identification as an auxiliary

By clicking accept or continuing to use the site, you agree to the terms outlined in our [Privacy Policy](#), [Terms of Service](#), and [Dataset License](#)

ACCEPT & CONTINUE

All Fields



FAQ

Contact Us

Sign In

## Study TNF- $\alpha$ gene polymorphism in Type 1 Diabetic Patients Using Amplification Refectory Mutation System ( ARMS ) technique

[Mona N. Al-Terehi](#), [Rana A. Ghaleb](#), [Shaimaa A. Al-Oubaidy](#), [Ali Alsaadi](#), [Haider K. Zaidan](#) • 2016

## Prevalence of Vitiligo and Associated Comorbidities in Korea

[Hem In Lee](#), [Mu-hyoung Lee](#), +14 authors [Sang Ho Oh](#) • Medicine • Yonsei medical journal • 2015

## A Clinical Study of Vitiligo in a Rural Set up of Gujarat

[Rita Vipul Vora](#), [Bhumi B. Patel](#), [Arvind H Chaudhary](#), [Malay J. Mehta](#), [Abhishek P. Pilani](#) • Medicine • Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine • 2014

## A descriptive study to characterize segmental vitiligo.

[Binod K. Khaitan](#), [Sushruta Kathuria](#), [M. Ramam](#) • Medicine • Indian journal of dermatology, venereology and leprology • 2012

## Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation.

[Ying Jin](#), [Tracey Ferrara](#), +5 authors [Richard A. Spritz](#) • Medicine, Biology • The Journal of investigative dermatology • 2012

## Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

[Richard A. Spritz](#) • Medicine • Thyroid : official journal of the American Thyroid Association • 2010

By clicking accept or continuing to use the site, you agree to the terms outlined in our [Privacy Policy](#), [Terms of Service](#), and [Dataset License](#)

ACCEPT &amp; CONTINUE

All Fields


[FAQ](#) [Contact Us](#) [Sign In](#)

[VIEW 1 EXCERPT](#)

### disease

Zhang X-J, Chen J-J, Liu J-B • 2010

## Related Papers



By clicking accept or continuing to use the site, you agree to the terms outlined in our [Privacy Policy](#), [Terms of Service](#), and [Dataset License](#)

[ACCEPT & CONTINUE](#)

All Fields

[FAQ](#) [Contact Us](#) [Sign In](#)

▼ Show More

2/0



Proudly built by **AI2** with the help of our **Collaborators** using these **Sources.**

[Terms of Service](#) · [Privacy Policy](#)

By clicking accept or continuing to use the site, you agree to the terms outlined in our [Privacy Policy](#), [Terms of Service](#), and [Dataset License](#)

ACCEPT & CONTINUE